Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the...
Transcript of Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the...
![Page 1: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/1.jpg)
S. Vincent Rajkumar, MDEdward W. and Betty Knight Scripps Professor of MedicineMayo ClinicRochester, Minnesota
Myeloma: Future Directions
This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical Care Options, LLC and the International Myeloma Foundation.
![Page 2: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/2.jpg)
Mayo Clinic College of MedicineMayo Clinic Comprehensive Cancer Center
Myeloma: Future Directions
S. Vincent RajkumarProfessor of Medicine, Mayo Clinic
@VincentRK
Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
![Page 3: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/3.jpg)
Speaker Name
No conflicts to disclose
![Page 4: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/4.jpg)
New Anti-CD38 antibodies
• TAK-079• MOR 202• SAR 442085
• Problem: Resistance• Abstract 721: Biallelic loss of BCMA (del 16p)
Samur. ASH 2020. Abstr 721
![Page 5: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/5.jpg)
Newer IMiDs/Cel Mods
• Iberdomide (CC-220) (Cereblon ligase modulator)− ASH 2020 Abstract 724: First Results of Iberdomide + Dara/Dex or
Iberdomide + Vd in RR MM
• CC-92480
Image: Matyskiela. J Med Chem 2018;61:535
![Page 6: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/6.jpg)
Bispecific Antibodies
AMG 701: Abstr 181, Saturday 12-1:30 PM
Teclistamab: Abstr 180, Saturday 12-1:30 PM
CC 93269Kumar, Rajkumar. JCO 2020. 38;18:2077.
![Page 7: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/7.jpg)
Novel Bispecifics
BFCR4350A: Bispecific targeting FcRH5 and CD3• Cohen et al, Abstract 292: Saturday Dec 5, 2-3:30 PM
Talquetamab: Bispecific targeting GPRC5D and CD3• Chari et al, Abstract 290: Saturday Dec 5, 2-3:30 PM
![Page 8: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/8.jpg)
Novel CAR-T Approaches
Yi Lin 2020
![Page 9: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/9.jpg)
Novel CAR-T
ALLO-647: allogenic, off-the-shelf CAR-T• Mailankody, et al. Abstract 129: Saturday, Dec 5 9:30-11 AM
Other approaches• Combined CD19-BCMA• Multiantigen targeting• Individualized targeting• CAR-NK
![Page 10: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/10.jpg)
Myeloma: Future State
Refractory to IMiD, PI, Anti-CD38
Multiple Relapse
Refractory to IMiD, PI, Anti CD38,
Alkylators, and Anti BCMA
Rajkumar SV © 2020
![Page 11: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/11.jpg)
Myeloma: Future State
Refractory to IMiD, PI, Anti-CD38
Multiple Relapse
Refractory to IMiD, PI, Anti CD38,
Alkylators, and Anti BCMA
Combinations with
Cyclophosphamide
that do not have
IMiD, PI, Anti CD38
Anti BCMA strategy
BCMA ADC
(eg., Belantamab)
Bispecific
Anti BCMA
BCMA CAR-Ts
Rajkumar SV © 2020
![Page 12: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/12.jpg)
Myeloma: Future State
Refractory to IMiD, PI, Anti-CD38
Multiple Relapse
Refractory to IMiD, PI, Anti CD38,
Alkylators, and Anti BCMA
Existing drugs:
Elotuzumab
Selinexor
Venetoclax
Panobinostat
Bendamustine
VDT PACE
New Drugs:
New Monoclonals
Iberdomide, CC-94480
New ADCs
New bi-specifics
New CAR-Ts
Combinations with
Cyclophosphamide
that do not have
IMiD, PI, Anti CD38
Anti BCMA strategy
BCMA ADC
(eg., Belantamab)
Bispecific
Anti BCMA
BCMA CAR-Ts
Rajkumar SV © 2020
![Page 13: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/13.jpg)
Panel Discussion: Future Directions for Myeloma
![Page 14: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/14.jpg)
Panel Discussion
Proposed 2021 Treatment Algorithms
![Page 15: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/15.jpg)
When Should Treatment Be Initiated?
Potential New Myeloma or Smoldering Myeloma
Any Myeloma Defining Events?•CRAB •≥60% PC •FLC ≥100 •MRI >1 focal lesion
Treat as Myeloma
Rajkumar SV © 2020
![Page 16: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/16.jpg)
When Should Treatment Be Initiated?
Potential New Myeloma or Smoldering Myeloma
Any Myeloma Defining Events?•CRAB •≥60% PC •FLC ≥100 •MRI >1 focal lesion
No Myeloma Defining Events (SMM)
Treat as Myeloma
High-Risk SMM(Median TTP ≈2 years)
Intermediate orLow-Risk SMM
Rajkumar SV © 2020
![Page 17: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/17.jpg)
When Should Treatment Be Initiated?
Potential New Myeloma or Smoldering Myeloma
Observation
Any Myeloma Defining Events?•CRAB •≥60% PC •FLC ≥100 •MRI >1 focal lesion
No Myeloma Defining Events (SMM)
Treat as Myeloma
High-Risk SMM(Median TTP ≈2 years)
Intermediate orLow-Risk SMM
Rajkumar SV © 2020
![Page 18: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/18.jpg)
When Should Treatment Be Initiated?
Potential New Myeloma or Smoldering Myeloma
Observation
Any Myeloma Defining Events?•CRAB •≥60% PC •FLC ≥100 •MRI >1 focal lesion
No Myeloma Defining Events (SMM)
Treat as Myeloma
High-Risk SMM(Median TTP ≈2 years)
Intermediate orLow-Risk SMM
Early Therapy With Len or Rd Clinical Trials
Rajkumar SV © 2020
![Page 19: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/19.jpg)
Not Transplant Candidate
Newly Diagnosed MM*
VRd x 9 months followed by Len maintenance
or
DRd
*Based on CALGB 100104, S0777, IFM-2009, CTN 0702, HOVON, MAIA, CASSIOPEIA¶ VTd/VCd if VRd not available
Myeloma: Frontline Treatment
Rajkumar SV © 2020
![Page 20: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/20.jpg)
Not Transplant Candidate
Newly Diagnosed MM*
Transplant Candidate
Auto-SCT followed byMaintenance
(Len for std risk;Len plus Bortezomib
for high risk)
Selected patients with standard risk MM:
VRd x4 cyclesLen Maintenance
Delayed Transplant
VRd x 9 months followed by Len maintenance
or
DRd
*Based on CALGB 100104, S0777, IFM-2009, CTN 0702, HOVON, MAIA, CASSIOPEIA¶ VTd/VCd if VRd not available
Myeloma: Frontline Treatment
VRd¶ or Dara-based quadruplet induction
Rajkumar SV © 2020
![Page 21: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/21.jpg)
Not Transplant Candidate
Newly Diagnosed MM
Transplant Candidate
Auto-SCTMaintenance
[Len for std risk;(Len)+PI-based for
high risk]Tandem for high-risk
1 - D-Rd
2 - VRD followed by Len
(VMP-Dara; Rd)
1 - VRD or Dara-based quad induction2 – VTD / VCD
P. Moreau
Myeloma: Frontline Treatment
No Delayed Transplant
Outside clinical trials
![Page 22: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/22.jpg)
First Relapse*
Not Refractory to Lenalidomide¶
DRd Alternatives including ifDara Refractory:
KRd or Ixa-Rd
*Consider salvage auto transplant in eligible patients¶Relapse occurring while off all therapy, or while on small doses of single-agent lenalidomide, or on bortezomib maintenance
Myeloma: First Relapse
Rajkumar SV © 2020
![Page 23: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/23.jpg)
Refractory to Lenalidomide
DVd, DPd
Isa-Pd
Alternatives including ifDara Refractory:
KPd or Dara-KPd, EPd, DKdFrail: Ixa-Pd
First Relapse*
Not Refractory to Lenalidomide¶
DRd Alternatives including ifDara Refractory:
KRd or Ixa-Rd
*Consider salvage auto transplant in eligible patients¶Relapse occurring while off all therapy, or while on small doses of single-agent lenalidomide, or on bortezomib maintenance
Myeloma: First Relapse
Rajkumar SV © 2020
![Page 24: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/24.jpg)
Refractory to Lenalidomide
Kd-dara, Kd-IsaPom-Vd,
(PomD-Dara, PD-Isa)
Alternatives:KPD, PDElo
Frail: Pd, IxaPd, PCD
First Relapse
Not Refractory to Lenalidomide
1 - DRdAlternatives including:
KRd, IRd, ERd;Kd-Dara / Kd-Isa
Myeloma: First Relapse
P. Moreau
! Challenge : patients progressing on frontline dara
![Page 25: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/25.jpg)
• Any first relapse options that have not been tried
(2 new drugs; triplet preferred)
First Relapse Options
Myeloma: Second or Higher Relapse
Rajkumar SV © 2020
![Page 26: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/26.jpg)
• Any first relapse options that have not been tried
(2 new drugs; triplet preferred)
First Relapse Options
• Belantamab mafodotin• VDT-PACE like anthracycline
containing regimens• Selinexor• Venetoclax (t11;14 only)• Melphalan• Bendamustine-based regimens• Adding panobinostat• Quadruplet regimens
Additional Options
Myeloma: Second or Higher Relapse
Rajkumar SV © 2020
![Page 27: Myeloma: Future Directions · Myeloma: Future Directions. This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical](https://reader035.fdocuments.in/reader035/viewer/2022071407/60ff2ecabd58894a5275b928/html5/thumbnails/27.jpg)
First Relapse Options
• Any first relapse options that have not been tried
(2 new drugs; triplet preferred)
Isa-Pd, or DPd, or DKd, or KPd
• Belamaf• VDT-PACE like anthracycline
containing regimens• Cyclo / benda / melphalan• Panobinostat + PI• Venetoclax [only t(11;14)]• Selinexor• Melflufen• CAR-T• Bispecific
Additional Options
Myeloma: Second or Higher Relapse
P. Moreau